- In January 2025, Senseonics has received FDA approval for its Eversense 365, an implantable CGM system that lasts up to a year, doubling the lifespan of its predecessor.This device provides real-time glucose readings every five minutes
- In October 2024, Companies such as Novo Nordisk and Eli Lilly have introduced smart insulin pens, such as the NovoPen 6 and Lilly’s Tempo Pen. These devices offer Bluetooth connectivity and companion apps, allowing for automated insulin delivery based on real-time glucose levels. Some models are now integrated with CGMs, enhancing personalized diabetes management
- In July 2023, CharmHealth and Bioverge jointly invested in My Diabetes Tutor, a startup focused on improving the lives of individuals with diabetes
- In May 2023, Medtronic agreed to acquire EOFlow, a manufacturer of insulin devices. The integration of EOFlow with Medtronic's Meal Detection Technology algorithm and advanced continuous glucose monitor (CGM) is expected to enhance the company's ability to serve a broader range of people with diabetes
- In April 2023, Undbio announced its plan to invest USD 100 million in constructing a US-based insulin manufacturing plant. The South Korean company intends to build a new facility in West Virginia to manufacture insulin and distribute its products within the country
